Nucleoside reverse transcriptase inhibitors (NRTIs) are known to produce painful neuropathies and to enhance states of pain hypersensitivity produced by HIV-1 infection. It has also been observed that in some neuropathic pain models, chemokines and their receptors are upregulated, perhaps contributing to the pain state. In order to understand if chemokines are involved in NRTI-mediated sensory neuropathies, we treated rats with the anti-retroviral drug, 2Ј,3Ј-dideoxycytidine (ddC), which is known to produce an extended period of hyperalgesia and allodynia. Using in situ hybridization, we observed that under normal conditions, CXCR4 chemokine receptors were widely expressed by satellite glia in the dorsal root ganglia (DRG) and Schwann cells in the sciatic nerve. A limited number of DRG neurons also expressed CXCR4 receptors. The chemokine SDF-1/CXCL12 was similarly expressed in glial cells in the DRG and peripheral nerve. Following a single administration of ddC, expression levels of CXCR4 mRNA in glia and neurons and SDF-1 mRNA in glia increased considerably. The functional nature of increased CXCR4 mRNA expression was conWrmed by measuring SDF-1 induced [Ca 2+ ] i increases in acutely isolated DRG neurons and glia. In contrast, the expression of the chemokine receptors CCR2 and CCR5 did not change following ddC treatment. Pain hypersensitivity produced by ddC could be inhibited by treatment with the CXCR4 antagonist, AMD3100. Hence, we postulate that NRTIs produce pain hypersensitivity through the upregulation of CXCR4 signaling in the DRG. Increased numbers of CXCR4 receptors would also explain the synergism observed between NRTI treatment and the proalgesic eVects of HIV-1 infection. Published by Elsevier Inc.
Introduction
HIV-1 infection is associated with several types of sensory and motor neuropathies (Kolson and GonzalezScarano, 2001; Luciano et al., 2003; Verma et al., 2005) . However, as HIV-1 does not replicate eVectively in neurons, the molecular and cellular basis of its eVects on the nervous system are unclear. It is thought that viral proteins, cytokines and neurotoxins may be released by infected macrophages or microglia and that these may ultimately mediate the eVects of the virus on neuronal function (White et al., 2005a) . HIV-1 infection has been successfully treated with nucleoside reverse transcriptase inhibitors (NRTIs). However, treatment with many of these drugs produces serious side eVects. In particular, NRTI treatment has been frequently shown to produce painful neuropathies that are indistinguishable from those resulting from HIV-1 infection (Dalakas, 2001) . NRTI-induced pain hypersensitivity can be severely limiting in individuals who are taking these drugs for their beneWcial eVects.
